2. Apoptosis Cytoskeleton Cell Cycle/DNA Damage
  3. Apoptosis Microtubule/Tubulin Mitosis
  4. Vincristine

Vincristine  (Synonyms: Leurocristine; NSC-67574; 22-Oxovincaleukoblastine)

Cat. No.: HY-N0488A Purity: 98.13%
COA
SDS
Handling Instructions Technical Support

Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.

For research use only. We do not sell to patients.

CAS No. : 57-22-7

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 74 publication(s) in Google Scholar

Other Forms of Vincristine:

Vincristine Related Antibodies

Top Publications Citing Use of Products

74 Publications Citing Use of MCE Vincristine

IF
Cell Proliferation/Viability Assay
Apoptosis Analysis
WB

    Vincristine purchased from MedChemExpress. Usage Cited in: Cell. 2025 Dec 11;188(25):7137-7154.e21.  [Abstract]

    Representative IF images showing the colocalization between mSARM1 and the noted chemo-induced cytosolic dsDNA in neural cells. The noted neural cells were treated with 20 μM CP, 100 μM CBP, or 0.5 μM VCR (Vincristine) for 36 h, followed by IF analyses. Green: dsDNA stained with anti-dsDNA antibody; red: mSARM1 stained with anti-SARM1 antibody; blue: DAPI. Scale bar, 10 μm.

    Vincristine purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Apr;44(4):469-490.  [Abstract]

    IC50 values of SGC7901VCR shNC and SGC7901VCR shA2B1 cells treated with VCR (Vincristine, 0.1-100 µg/mL; 48 h) and 5‐Fu (0.1-100 µg/mL; 48 h).

    Vincristine purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Apr;44(4):469-490.  [Abstract]

    Apoptosis of SGC7901VCRshNC and SGC7901VCR shA2B1 cells treated with VCR (Vincristine, 1 or 15 µg/mL; 48 h) and 5‐Fu (1 or 20 µg/mL; 48 h).

    Vincristine purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716.  [Abstract]

    The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.

    Vincristine purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64.  [Abstract]

    Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).

    Vincristine purchased from MedChemExpress. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839.  [Abstract]

    TF-1 derivative cell lines were incubated with the indicated concentrations of vincristine (20 nM) or Regorafenib (10 μM) for 2 days, and the proportions of apoptotic cells were determined by staining with AnnexinV. Mean + SEM, n = 3.

    Vincristine purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2019 May 1:128:574-582.  [Abstract]

    SGC7901/DDP or SGC7901/VCR (Vincristine) cells are transfected with si-Con or si-ERK, and transfection efficiency is evaluated by western blot assay at 48 h post transfection.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas[1][2][3][4][5][6][7][8].

    Cellular Effect
    Cell Line Type Value Description References
    4T1 IC50
    0.02 μM
    Compound: vincristine
    Cytotoxicity against mouse 4T1 cells by MTT assay
    Cytotoxicity against mouse 4T1 cells by MTT assay
    		[PMID: 16539377]
    786-0 IC50
    1.2 nM
    Compound: vincristine
    Antiproliferative activity against MDR-1 overexpressing human 786-0 cells in presence of MDR1 inhibitor verapamil
    Antiproliferative activity against MDR-1 overexpressing human 786-0 cells in presence of MDR1 inhibitor verapamil
    		[PMID: 21774499]
    786-0 IC50
    37 nM
    Compound: vincristine
    Antiproliferative activity against MDR-1 overexpressing human 786-0 cells
    Antiproliferative activity against MDR-1 overexpressing human 786-0 cells
    		[PMID: 21774499]
    A 172 IC50
    0.7 ng/mL
    Compound: vincristine
    Cytotoxicity against human A172 cells after 6 days
    Cytotoxicity against human A172 cells after 6 days
    		[PMID: 18044843]
    A-375 IC50
    3.5 nM
    Compound: VC
    Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    A2780 EC50
    3.4 nM
    Compound: Vincristine
    Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
    Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
    		[PMID: 31047749]
    A2780 EC50
    3.9 nM
    Compound: Vincristine
    Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
    Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
    		[PMID: 31047749]
    A2780 IC50
    0.026 μM
    Compound: VCT
    Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27149641]
    A2780 IC50
    0.03 μM
    Compound: VCR
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A2780 IC50
    0.17 μM
    Compound: VCR
    Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A2780 IC50
    0.9 nM
    Compound: VCR
    Cytotoxicity againt human A2780 cells
    Cytotoxicity againt human A2780 cells
    		[PMID: 17239597]
    A2780 IC50
    0.93 μM
    Compound: VCT
    Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
    Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
    		[PMID: 25061803]
    A2780 IC50
    3.1 nM
    Compound: vincristine
    Growth inhibition of human A2780 cells
    Growth inhibition of human A2780 cells
    		[PMID: 17490878]
    A2780 ADR IC50
    311 nM
    Compound: vincristine
    Growth inhibition of multidrug-resistant human 2780AD cells
    Growth inhibition of multidrug-resistant human 2780AD cells
    		[PMID: 17490878]
    A2780 ADR IC50
    895 nM
    Compound: VCR
    Cytotoxicity againt multidrug-resistant human 2780AD cells
    Cytotoxicity againt multidrug-resistant human 2780AD cells
    		[PMID: 17239597]
    A549 ED50
    0.004 μg/mL
    Compound: vincristine
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    		[PMID: 18473435]
    A549 ED50
    4.8 nM
    Compound: Vincristine
    Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay
    		[PMID: 21296579]
    A549 GI50
    0.007 μM
    Compound: VCR
    Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay
    		[PMID: 21284385]
    A549 GI50
    0.02 μM
    Compound: Vincristine
    Inhibition of human non-small cell lung cancer A549 cell proliferation
    Inhibition of human non-small cell lung cancer A549 cell proliferation
    		[PMID: 15546733]
    A549 IC50
    0.03 μM
    Compound: vincristine
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 16539377]
    A549 IC50
    0.03 μM
    Compound: vincristrine
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    A549 IC50
    0.04 μM
    Compound: vincristrine
    Cytotoxicity against human A549 cells by SRB microtiter plate assay
    Cytotoxicity against human A549 cells by SRB microtiter plate assay
    		[PMID: 17585747]
    A549 IC50
    0.056 μM
    Compound: VCT
    Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
    Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
    		[PMID: 25061803]
    A549 IC50
    0.06 μM
    Compound: VCR
    Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A549 IC50
    0.061 μM
    Compound: VCT
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27149641]
    A549 IC50
    0.36 μM
    Compound: vincristine
    Cytotoxicity against A549 cells after 48 hrs by MTT assay
    Cytotoxicity against A549 cells after 48 hrs by MTT assay
    		[PMID: 17604394]
    A549 IC50
    0.56 μM
    Compound: VCR
    Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A549 IC50
    0.561 μM
    Compound: VCT
    Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 27149641]
    A549 IC50
    0.8 μM
    Compound: Vincristine
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		10.1039/C6MD00178E
    A549 IC50
    18 nM
    Compound: VCR
    In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation
    In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation
    		[PMID: 11140731]
    A549 IC50
    2.5 μM
    Compound: VCR
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 19679470]
    A549 IC50
    36.83 nM
    Compound: Vincristine
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    		[PMID: 26318055]
    A549 IC50
    53 nM
    Compound: VCR
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23981529]
    AGS IC50
    < 0.12 μM
    Compound: vincristine
    Cytotoxicity against AGS cells after 48 hrs by MTT assay
    Cytotoxicity against AGS cells after 48 hrs by MTT assay
    		[PMID: 17604394]
    ARO IC50
    0.0001 μM
    Compound: vincristine
    Cytotoxicity against human Aro cells by MTT assay
    Cytotoxicity against human Aro cells by MTT assay
    		[PMID: 16539377]
    ARO IC50
    0.0003 μM
    Compound: vincristrine
    Cytotoxicity against human Aro cells after 72 hrs by MTT assay
    Cytotoxicity against human Aro cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    B16 IC50
    0.5 μM
    Compound: Vincristine
    Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 26934105]
    B16-F10 IC50
    0.01 μM
    Compound: Vincristine
    Cytotoxicity against mouse B16F10 cells by MTT assay
    Cytotoxicity against mouse B16F10 cells by MTT assay
    		[PMID: 28105271]
    BGC-823 IC50
    0.066 μg/mL
    Compound: VCR
    Cytotoxicity against human BGC823 cells
    Cytotoxicity against human BGC823 cells
    		[PMID: 15387638]
    BHK-21 IC50
    1.08 μM
    Compound: Vincristine
    Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 31404864]
    BHK-21 IC50
    1.51 nM
    Compound: vincristine
    Cytotoxicity against hamster BHK21 cells after 72 hrs by MTT assay
    Cytotoxicity against hamster BHK21 cells after 72 hrs by MTT assay
    		[PMID: 17646169]
    BHK-21 IC50
    9.42 nM
    Compound: vincristine
    Cytotoxicity against human MRP1 expressing hamster BHK21 cells after 72 hrs by MTT assay
    Cytotoxicity against human MRP1 expressing hamster BHK21 cells after 72 hrs by MTT assay
    		[PMID: 17646169]
    BNL IC50
    0.08 μM
    Compound: vincristine
    Cytotoxicity against mouse BNL cells by MTT assay
    Cytotoxicity against mouse BNL cells by MTT assay
    		[PMID: 16539377]
    BT-474 IC50
    2.9 nM
    Compound: VC
    Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    BXPC-3 IC50
    > 500 nM
    Compound: VCR
    Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23981529]
    Bel-7402 IC50
    0.04 μM
    Compound: VCR
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 19111465]
    Bel-7402 IC50
    4.2 nM
    Compound: Vincristine
    Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    C6 EC50
    6.2 x 10-6 M
    Compound: vincristine
    Inhibition of tubulin polymerization in rat C6 cells after 4 hrs
    Inhibition of tubulin polymerization in rat C6 cells after 4 hrs
    		[PMID: 8988604]
    CAKI-1 IC50
    5.7 nM
    Compound: VC
    Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    CAL-51 GI50
    0.089 μM
    Compound: Vincristine
    Antiproliferative activity against human CAL-51 cells incubated for 72 hrs by SRB proliferation assay
    Antiproliferative activity against human CAL-51 cells incubated for 72 hrs by SRB proliferation assay
    		[PMID: 37849542]
    CCRF-CEM EC50
    0.3666 μM
    Compound: vincristine
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    CCRF-CEM EC50
    0.5972 μM
    Compound: vincristine
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    CCRF-CEM IC50
    0.025 μg/mL
    Compound: vincristine
    Inhibition against CRFF-CEM-T-Cell leukemic cell line
    Inhibition against CRFF-CEM-T-Cell leukemic cell line
    		[PMID: 2769688]
    CCRF-CEM IC50
    0.06 μg/mL
    Compound: 1, VCR
    Cytotoxicity against human CCRF-CEM cells
    Cytotoxicity against human CCRF-CEM cells
    		[PMID: 9392881]
    CCRF-CEM IC50
    0.17 nM
    Compound: vincristine
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    CCRF-CEM IC50
    2.13 nM
    Compound: VCR
    Cytotoxicity against human CCRF-CEM cells assessed as decrease in cell proliferation after 72 hrs by Alamar blue assay
    Cytotoxicity against human CCRF-CEM cells assessed as decrease in cell proliferation after 72 hrs by Alamar blue assay
    		[PMID: 28064078]
    CCRF-CEM IC50
    2.32 nM
    Compound: vincristine
    Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by Alamar Blue assay
    Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by Alamar Blue assay
    		[PMID: 24583355]
    CCRF-CEM IC50
    2128 nM
    Compound: vincristine
    Cytotoxicity against vinblastine-resistant human CCRF-CEM cells assessed as growth inhibition after 72 hrs by Alamar Blue assay
    Cytotoxicity against vinblastine-resistant human CCRF-CEM cells assessed as growth inhibition after 72 hrs by Alamar Blue assay
    		[PMID: 24583355]
    CCRF-CEM IC50
    3 nM
    Compound: Vincristine
    Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 31419740]
    CHO CC50
    1.15 μg/mL
    Compound: vincristine
    Cytotoxicity against CHO cells after 48 hrs by MTT assay
    Cytotoxicity against CHO cells after 48 hrs by MTT assay
    		[PMID: 11858754]
    CNS carcinoma cell GI50
    0.13 μM
    Compound: Vincristine
    Cell growth inhibition of human CNS carcinoma cells incubated for 48 hrs by SRB assay
    Cell growth inhibition of human CNS carcinoma cells incubated for 48 hrs by SRB assay
    		[PMID: 38640869]
    COLO 205 IC50
    2.6 nM
    Compound: Vincristine
    Cytotoxicity against COLO205 cells
    Cytotoxicity against COLO205 cells
    		[PMID: 17228873]
    COLO 205 IC50
    2.6 nM
    Compound: Vincristine
    Antiproliferative activity against human COLO205 cells after 24 hrs by MTS assay
    Antiproliferative activity against human COLO205 cells after 24 hrs by MTS assay
    		[PMID: 19041247]
    COLO 205 IC50
    2.6 nM
    Compound: vincristine
    Cytotoxicity against COLO205 cells
    Cytotoxicity against COLO205 cells
    		[PMID: 17416524]
    COLO 320DM IC50
    0.46 μg/mL
    Compound: vincristine
    Cytotoxicity against human Colo320DM cells by MTT assay
    Cytotoxicity against human Colo320DM cells by MTT assay
    		[PMID: 16480866]
    COLO 320DM IC50
    1.5 μg/mL
    Compound: vincristine
    Cytotoxicity against human Colo320DM cells by clonogenic assay
    Cytotoxicity against human Colo320DM cells by clonogenic assay
    		[PMID: 16480866]
    Cancer cell lines GI50
    0.1 μM
    Compound: vincristine
    Cytotoxicity against human CNS cancer cells after 48 hrs
    Cytotoxicity against human CNS cancer cells after 48 hrs
    		[PMID: 23685944]
    Cancer cell lines GI50
    0.1 μM
    Compound: vincristine
    Cytotoxicity against human colon cancer cells after 48 hrs
    Cytotoxicity against human colon cancer cells after 48 hrs
    		[PMID: 23685944]
    Cancer cell lines GI50
    0.1 μM
    Compound: vincristine
    Cytotoxicity against human prostate cancer cells after 48 hrs
    Cytotoxicity against human prostate cancer cells after 48 hrs
    		[PMID: 23685944]
    Cancer cell lines GI50
    0.3 μM
    Compound: vincristine
    Cytotoxicity against human breast cancer cells after 48 hrs
    Cytotoxicity against human breast cancer cells after 48 hrs
    		[PMID: 23685944]
    Cancer cell lines GI50
    0.3 μM
    Compound: vincristine
    Cytotoxicity against human ovarian cancer cells after 48 hrs
    Cytotoxicity against human ovarian cancer cells after 48 hrs
    		[PMID: 23685944]
    Cancer cell lines GI50
    0.3 μM
    Compound: vincristine
    Cytotoxicity against human renal cancer cells after 48 hrs
    Cytotoxicity against human renal cancer cells after 48 hrs
    		[PMID: 23685944]
    DU-145 GI50
    0.018 μM
    Compound: VCR
    Antiproliferative activity against human DU145 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human DU145 cells after 3 days by sulforhodamine B assay
    		[PMID: 21284385]
    DU-145 IC50
    0.00112 μM
    Compound: vincristine
    In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation
    In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation
    		[PMID: 11728191]
    DU-145 IC50
    0.0085 μM
    Compound: vincristrine
    Cytotoxicity against human DU145 cells by SRB microtiter plate assay
    Cytotoxicity against human DU145 cells by SRB microtiter plate assay
    		[PMID: 17585747]
    Flp-In-293 IC50
    < 40 μM
    Compound: Vincristine
    Antiproliferative activity against human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition incubated for 72 hrs by SRB assay
    Antiproliferative activity against human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition incubated for 72 hrs by SRB assay
    		[PMID: 35751979]
    HCT-116 EC50
    0.058 μM
    Compound: vincristine
    Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay
    Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay
    		[PMID: 18197614]
    HCT-116 GI50
    0.001 μM
    Compound: Vincristine
    Compound was tested for growth inhibition of human colon carcinoma HCT116 cell line
    Compound was tested for growth inhibition of human colon carcinoma HCT116 cell line
    		[PMID: 15546733]
    HCT-116 GI50
    0.006 μM
    Compound: Vincristine
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by SRB proliferation assay
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by SRB proliferation assay
    		[PMID: 37849542]
    HCT-116 IC50
    48.427 nM
    Compound: Vincristine
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    		[PMID: 37544183]
    HCT-116 IC50
    7 nM
    Compound: 2
    Cytotoxicity against human HCT116 cells
    Cytotoxicity against human HCT116 cells
    		[PMID: 22247789]
    HCT-8 ED50
    0.02 μg/mL
    Compound: vincristine
    Cytotoxicity against human HCT8 cells by sulforhodamine B assay
    Cytotoxicity against human HCT8 cells by sulforhodamine B assay
    		[PMID: 18473435]
    HCT-8 ED50
    24.2 nM
    Compound: Vincristine
    Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay
    		[PMID: 21296579]
    HCT-8 GI50
    0.036 μM
    Compound: VCR
    Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay
    		[PMID: 21284385]
    HCT-8 IC50
    0.173 μM
    Compound: VCR
    Antiproliferative activity against human HCT-8 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-8 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 37856840]
    HCT-8 IC50
    0.217 μM
    Compound: VCR
    Antiproliferative activity against human HCT-8 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-8 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34649064]
    HCT-8 IC50
    0.35 μM
    Compound: VCR
    Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    HCT-8 IC50
    0.35 μM
    Compound: VCT
    Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27149641]
    HCT-8 IC50
    1.9 μM
    Compound: VCT
    Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
    Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
    		[PMID: 25061803]
    HCT-8 IC50
    7.86 μM
    Compound: VCR
    Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    HEK-293T IC50
    94.95 μM
    Compound: VCR
    Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 37084600]
    HEK293 IC50
    11 μM
    Compound: Vincristine
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    		[PMID: 22541068]
    HEK293 IC50
    25.8 nM
    Compound: VC
    Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    HEK293 IC50
    44 μM
    Compound: Vincristine
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    		[PMID: 22541068]
    HEL IC50
    5.97 μM
    Compound: Vincristine
    Antiproliferative activity against HEL cells after 48 hrs by MTT assay
    Antiproliferative activity against HEL cells after 48 hrs by MTT assay
    		[PMID: 30109000]
    HEp-2 CC50
    0.05 μg/mL
    Compound: vincristine
    Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay
    Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay
    		[PMID: 11858754]
    HEp-2 IC50
    0.003 μg/mL
    Compound: Vincristine
    Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay
    Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay
    		[PMID: 19027993]
    HL-60 IC50
    0.008 μg/mL
    Compound: Vincristine
    Antiproliferative activity against human HL60 cells incubated for 2 days by MTT assay
    Antiproliferative activity against human HL60 cells incubated for 2 days by MTT assay
    		[PMID: 32527555]
    HL-60 IC50
    0.06 μM
    Compound: vincristine
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    HL-60 IC50
    0.87 nM
    Compound: Vincristine
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 19711971]
    HL-60 IC50
    1.8 μM
    Compound: Vincristine
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 29133061]
    HL60/MX2 EC50
    0.06088 μM
    Compound: vincristine
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    		[PMID: 19743858]
    HT-1080 IC50
    0.3 nM
    Compound: VC
    Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    HT-29 IC50
    0.001 μM
    Compound: Vincristine
    Tested for cytotoxicity against HT-29 (wt)cells
    Tested for cytotoxicity against HT-29 (wt)cells
    		[PMID: 12502374]
    HT-29 IC50
    0.01 μM
    Compound: vincristine
    Cytotoxicity against human HT29 cells by MTT assay
    Cytotoxicity against human HT29 cells by MTT assay
    		[PMID: 16539377]
    HT-29 IC50
    0.01 μM
    Compound: vincristrine
    Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    HT-29 IC50
    0.017 μM
    Compound: Vincristine
    Tested for cytotoxicity against HT-29 (MDR)cells
    Tested for cytotoxicity against HT-29 (MDR)cells
    		[PMID: 12502374]
    HT-29 IC50
    0.21 μM
    Compound: vincristine
    Cytotoxicity against HT29 cells after 48 hrs by MTT assay
    Cytotoxicity against HT29 cells after 48 hrs by MTT assay
    		[PMID: 17604394]
    HT-29 IC50
    1.74 μM
    Compound: Vincristine
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33477020]
    HT-29 IC50
    12 nM
    Compound: VCR
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23981529]
    HT-29 IC50
    2.06 nM
    Compound: vincristine
    Inhibitory activity against growth of HT-29 cell line
    Inhibitory activity against growth of HT-29 cell line
    		[PMID: 9554885]
    HT-29 IC50
    5.3 μM
    Compound: VCR
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 19679470]
    HT-29 IC50
    7 nM
    Compound: Vincristine
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    		[PMID: 2778449]
    HT-29 IC50
    uM μM
    Compound: vincristine
    In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation
    In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation
    		[PMID: 11728191]
    HaCaT IC50
    0.65 μM
    Compound: Vincristine
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 26934105]
    HeLa CC50
    0.05 μg/mL
    Compound: Vincristine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 19217699]
    HeLa CC50
    0.05 μg/mL
    Compound: vincristine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 11858754]
    HeLa GI50
    1.7 nM
    Compound: 2
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 19147348]
    HeLa IC50
    0.0043 μM
    Compound: vincristine
    Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
    		[PMID: 23855338]
    HeLa IC50
    0.005 μM
    Compound: vincristine
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 16539377]
    HeLa IC50
    0.005 μM
    Compound: vincristrine
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    HeLa IC50
    0.014 μg/mL
    Compound: Vincristine (VCR)
    Cytotoxicity tested against Hela C1 cells
    Cytotoxicity tested against Hela C1 cells
    		[PMID: 10612603]
    HeLa IC50
    0.015 μM
    Compound: VCR
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    		[PMID: 24360827]
    HeLa IC50
    0.015 μM
    Compound: VCR
    Cytotoxicity against human HeLa cells after 3 days by SRB assay
    Cytotoxicity against human HeLa cells after 3 days by SRB assay
    		[PMID: 26927488]
    HeLa IC50
    0.04 μM
    Compound: Vincristine
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 26270803]
    HeLa IC50
    0.051 μg/mL
    Compound: Vincristine (VCR)
    Cytotoxicity tested against Hela T5 cells
    Cytotoxicity tested against Hela T5 cells
    		[PMID: 10612603]
    HeLa IC50
    0.05 μg/mL
    Compound: Vincristine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 20619938]
    HeLa IC50
    0.141 μM
    Compound: Vincristine
    Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
    Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
    		[PMID: 29624387]
    HeLa IC50
    1 nM
    Compound: VC
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    HeLa IC50
    4.1 μM
    Compound: Vincristine
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		10.1039/C6MD00178E
    HeLa IC50
    70 μM
    Compound: Vincristine
    TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells
    TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells
    		[PMID: 8621644]
    HeLa S3 IC50
    < 40 μM
    Compound: Vincristine
    Antiproliferative activity against drug-sensitive human HeLaS3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
    Antiproliferative activity against drug-sensitive human HeLaS3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
    		[PMID: 35751979]
    Hep 3B2 GI50
    0.0029 μM
    Compound: Vincristine
    Anticancer activity against human Hep3B cells after 3 days by SRB assay
    Anticancer activity against human Hep3B cells after 3 days by SRB assay
    		[PMID: 20735140]
    Hep 3B2 GI50
    6.86 μM
    Compound: Vincristine
    Anticancer activity against vincristine-resistant human Hep3B cells after 3 days by SRB assay
    Anticancer activity against vincristine-resistant human Hep3B cells after 3 days by SRB assay
    		[PMID: 20735140]
    Hep 3B2 IC50
    > 100 nM
    Compound: Vincristine
    Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    HepG2 ED50
    2.9 nM
    Compound: Vincristine
    Antiproliferative activity against human HepG2 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human HepG2 cells after 3 days by sulforhodamine B assay
    		[PMID: 21296579]
    HepG2 IC50
    0.042 μg/mL
    Compound: Vincristine
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 29133050]
    HepG2 IC50
    0.07 μM
    Compound: Vincristine
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 26270803]
    HepG2 IC50
    0.2 μM
    Compound: vincristine
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 16539377]
    HepG2 IC50
    0.2 μM
    Compound: vincristrine
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    HepG2 IC50
    210 nM
    Compound: VCR
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23981529]
    HepG2 IC50
    3.7 μM
    Compound: VCR
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 19679470]
    HepG2 IC50
    93.67 μM
    Compound: VCR
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 37084600]
    HepG2 IC50
    > 100 nM
    Compound: Vincristine
    Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    Huh-7 IC50
    20 nM
    Compound: Vincristine
    Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    Jurkat IC50
    3.1 ng/mL
    Compound: Vincristine
    Growth inhibition of human Jurkat cells
    Growth inhibition of human Jurkat cells
    		[PMID: 19026536]
    K562 IC50
    0.004 μM
    Compound: VCR
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    K562 IC50
    0.006 μM
    Compound: Vincristine
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 17889544]
    K562 IC50
    0.021 μM
    Compound: VCR
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 30530194]
    K562 IC50
    0.1 nM
    Compound: vincristine
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    		[PMID: 22582991]
    K562 IC50
    0.178 μM
    Compound: VCR
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    		[PMID: 29678463]
    K562 IC50
    17.287 nM
    Compound: Vincristine
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    		[PMID: 37544183]
    K562 IC50
    178 nM
    Compound: Vincristine
    Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 method
    Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 method
    		[PMID: 32992133]
    K562 IC50
    5.36 μM
    Compound: Vincristine
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 30109000]
    K562/A02 IC50
    0.926 μM
    Compound: VCR
    Antiproliferative activity against human K562/A02 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562/A02 cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    K562/VCR IC50
    4.73 μM
    Compound: Vincristine
    Antiproliferative activity against human K562/VCR cells incubated for 72 hrs by CCK8 method
    Antiproliferative activity against human K562/VCR cells incubated for 72 hrs by CCK8 method
    		[PMID: 32992133]
    K562/VCR IC50
    4.737 μM
    Compound: VCR
    Antiproliferative activity against human K562/VCR cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562/VCR cells after 72 hrs by CCK8 assay
    		[PMID: 29678463]
    K562/VCR IC50
    5.06 μM
    Compound: VCR
    Antiproliferative activity against human VCR-resistant K562/VCR cells after 72 hrs by MTT assay
    Antiproliferative activity against human VCR-resistant K562/VCR cells after 72 hrs by MTT assay
    		[PMID: 30530194]
    KB EC50
    2.4 nM
    Compound: VCR
    Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry
    Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry
    		[PMID: 21705223]
    KB EC50
    2.4 nM
    Compound: Vincristine
    Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis
    Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis
    		[PMID: 19220018]
    KB EC50
    2.4 nM
    Compound: Vincristine
    Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
    Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
    		[PMID: 20537765]
    KB EC50
    2.4 nM
    Compound: vincristine
    Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase
    Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase
    		[PMID: 17181164]
    KB EC50
    2.4 nM
    Compound: vincristine
    Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis
    Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis
    		[PMID: 17973361]
    KB ED50
    0.015 μg/mL
    Compound: vincristine
    Cytotoxicity against human KB cells by sulforhodamine B assay
    Cytotoxicity against human KB cells by sulforhodamine B assay
    		[PMID: 18473435]
    KB ED50
    1.3 μg/mL
    Compound: vincristine
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 7130986]
    KB ED50
    2.4 nM
    Compound: Vincristine
    Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay
    		[PMID: 21296579]
    KB GI50
    0.00186 μM
    Compound: Vin
    Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay
    Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay
    		[PMID: 32171161]
    KB GI50
    0.004 μM
    Compound: VCR
    Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay
    		[PMID: 21284385]
    KB GI50
    2 nM
    Compound: VCR
    Cytotoxicity against human KB cells at 4 uM after 48 hrs by SRB assay
    Cytotoxicity against human KB cells at 4 uM after 48 hrs by SRB assay
    		[PMID: 22465634]
    KB IC50
    0.001 μM
    Compound: vincristine
    Antiproliferative activity against drug-resistant tumor cell line KBwt.
    Antiproliferative activity against drug-resistant tumor cell line KBwt.
    		[PMID: 10411476]
    KB IC50
    0.0028 μM
    Compound: vincristine
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 17939738]
    KB IC50
    0.003 μM
    Compound: VCR
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B and MTT assay
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B and MTT assay
    		[PMID: 22119124]
    KB IC50
    0.0033 μM
    Compound: Vincristine
    Cytotoxicity against human vincristine-sensitive KB cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human vincristine-sensitive KB cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26717050]
    KB IC50
    0.004 μM
    Compound: Vincristine
    Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method
    Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method
    		[PMID: 14761187]
    KB IC50
    0.005 μM
    Compound: vincristine
    Antiproliferative activity against drug-resistant tumor cell line KBCamp.
    Antiproliferative activity against drug-resistant tumor cell line KBCamp.
    		[PMID: 10411476]
    KB IC50
    0.006 μM
    Compound: Vincristine
    Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%
    Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%
    		[PMID: 12431048]
    KB IC50
    0.006 μM
    Compound: vincristrine
    Cytotoxicity against human KB cells by SRB microtiter plate assay
    Cytotoxicity against human KB cells by SRB microtiter plate assay
    		[PMID: 17585747]
    KB IC50
    0.007 μg/mL
    Compound: vincristine
    Cytotoxicity against vincristine-sensitive human KB cells
    Cytotoxicity against vincristine-sensitive human KB cells
    		[PMID: 25333996]
    KB IC50
    0.01 μM
    Compound: VCR
    Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20353152]
    KB IC50
    0.014 μg/mL
    Compound: 5
    Compound was evaluated for its cytotoxicity against vincristine-sensitive KB/S human oral epidermoid carcinoma cell lines.
    Compound was evaluated for its cytotoxicity against vincristine-sensitive KB/S human oral epidermoid carcinoma cell lines.
    		[PMID: 9873417]
    KB IC50
    0.0167 μM
    Compound: vincristine
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 17608533]
    KB IC50
    0.02 μM
    Compound: VCR
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    		[PMID: 21761866]
    KB IC50
    0.02 μg/mL
    Compound: vincristine
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 16480866]
    KB IC50
    0.035 μM
    Compound: vincristine
    Antiproliferative activity against drug-resistant tumor cell line KB7D.
    Antiproliferative activity against drug-resistant tumor cell line KB7D.
    		[PMID: 10411476]
    KB IC50
    0.036 μM
    Compound: VCR
    Antiproliferative activity against human KB cells after 72 hrs by MTT assay
    Antiproliferative activity against human KB cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    KB IC50
    0.05 μM
    Compound: Vincristine
    Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method
    Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method
    		[PMID: 14761187]
    KB IC50
    0.05 μM
    Compound: vincristine
    Antiproliferative activity against drug-resistant tumor cell line KBV20C.
    Antiproliferative activity against drug-resistant tumor cell line KBV20C.
    		[PMID: 10411476]
    KB IC50
    0.2 nM
    Compound: VCR
    Antiproliferative activity against human KB cells after 72 hrs by SRB assay
    Antiproliferative activity against human KB cells after 72 hrs by SRB assay
    		[PMID: 28333459]
    KB IC50
    0.2 μM
    Compound: Vincristine
    Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method
    Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method
    		[PMID: 14761187]
    KB IC50
    0.21 nM
    Compound: VCR
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 30455148]
    KB IC50
    0.25 μg/mL
    Compound: vincristine
    Cytotoxicity against human KB cells by clonogenic assay
    Cytotoxicity against human KB cells by clonogenic assay
    		[PMID: 16480866]
    KB IC50
    0.35 μM
    Compound: vincristine
    Antiproliferative activity against drug-resistant tumor cell line KBMDR.
    Antiproliferative activity against drug-resistant tumor cell line KBMDR.
    		[PMID: 10411476]
    KB IC50
    0.4 nM
    Compound: Vincristine
    Antiproliferative activity against human KB cells
    Antiproliferative activity against human KB cells
    		[PMID: 25059503]
    KB IC50
    0.4 nM
    Compound: vincristine
    Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay
    Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay
    		[PMID: 19053773]
    KB IC50
    0.4 nM
    Compound: vincristine
    Growth inhibition of human KB cells after 72 hrs by methylene blue assay
    Growth inhibition of human KB cells after 72 hrs by methylene blue assay
    		[PMID: 22060033]
    KB IC50
    0.46 μg/mL
    Compound: Vincristine
    Cytotoxicity in human KB cells assessed as reduction in cell viability
    Cytotoxicity in human KB cells assessed as reduction in cell viability
    		[PMID: 28760313]
    KB IC50
    0.6 nM
    Compound: Vincristine
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
    		[PMID: 24106982]
    KB IC50
    0.65 nM
    Compound: Vincristine
    Antiproliferative activity against human KB cells after 48 hrs by MTT assay
    Antiproliferative activity against human KB cells after 48 hrs by MTT assay
    		[PMID: 29795767]
    KB IC50
    0.72 nM
    Compound: VCR
    Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
    		[PMID: 29294282]
    KB IC50
    0.8 nM
    Compound: Vincristine
    Cytotoxicity against human vincristine-sensitive KB cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human vincristine-sensitive KB cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 33872002]
    KB IC50
    0.8 μM
    Compound: Vincristine
    Cytotoxicity against human vincristine-resistant KB cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human vincristine-resistant KB cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 33872002]
    KB IC50
    0.87 nM
    Compound: Vincristine
    Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    		[PMID: 26318055]
    KB IC50
    0.9 nM
    Compound: Vincristine
    Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
    Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
    		[PMID: 24657567]
    KB IC50
    0.9 nM
    Compound: Vincristine
    Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay
    Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay
    		[PMID: 26160020]
    KB IC50
    1 μM
    Compound: Vincristine
    Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method
    Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method
    		[PMID: 14761187]
    KB IC50
    1.05 μg/mL
    Compound: 5
    Compound was evaluated for its cytotoxicity against vincristine-resistant KB/VJ300 human oral epidermoid carcinoma cell lines.
    Compound was evaluated for its cytotoxicity against vincristine-resistant KB/VJ300 human oral epidermoid carcinoma cell lines.
    		[PMID: 9873417]
    KB IC50
    1.2 nM
    Compound: vincristine
    Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay
    Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay
    		[PMID: 19053773]
    KB IC50
    1.29 μM
    Compound: VCR
    Cytotoxicity against vincristine-resistant human KB cells over expressing P-glycoprotein after 72 hrs by SRB assay
    Cytotoxicity against vincristine-resistant human KB cells over expressing P-glycoprotein after 72 hrs by SRB assay
    		[PMID: 21761866]
    KB IC50
    1.61 μM
    Compound: VCR
    Cytotoxicity against vincristine-selected multi drug-resistant human KB cells after 72 hrs by sulforhodamine B and MTT assay
    Cytotoxicity against vincristine-selected multi drug-resistant human KB cells after 72 hrs by sulforhodamine B and MTT assay
    		[PMID: 22119124]
    KB IC50
    139 nM
    Compound: VCR
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23981529]
    KB IC50
    17.6 nM
    Compound: vincristine
    Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay
    Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay
    		[PMID: 19053773]
    KB IC50
    2.11 nM
    Compound: vincristine
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    		[PMID: 23360284]
    KB IC50
    2.2 nM
    Compound: Vincristine
    Antiproliferative activity against KB cells expressing MDR1
    Antiproliferative activity against KB cells expressing MDR1
    		[PMID: 17228873]
    KB IC50
    2.2 nM
    Compound: Vincristine
    Antiproliferative activity against human KB cells after 3 days by SRB assay
    Antiproliferative activity against human KB cells after 3 days by SRB assay
    		[PMID: 19041247]
    KB IC50
    2.2 nM
    Compound: vincristine
    Antiproliferative activity against KB cells
    Antiproliferative activity against KB cells
    		[PMID: 17416524]
    KB IC50
    5 nM
    Compound: Vincristine
    Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 31419740]
    KB IC50
    6.07 nM
    Compound: VCR
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 20724170]
    KB IC50
    6.7 nM
    Compound: Vincristine
    Antiproliferative activity against human KB cells measured after 72 hrs by SRB assay
    Antiproliferative activity against human KB cells measured after 72 hrs by SRB assay
    		[PMID: 34794817]
    KB IC50
    7.9 nM
    Compound: vincristine
    Cytotoxicity against human KB cells assessed as cell viability after 48 hrs by MTS assay
    Cytotoxicity against human KB cells assessed as cell viability after 48 hrs by MTS assay
    		[PMID: 18295490]
    KB IC50
    90.1 nM
    Compound: vincristine
    Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay
    Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay
    		[PMID: 19053773]
    KB IC50
    > 100000 nM
    Compound: VCR
    Cytotoxicity against vincristine-resistant human KB cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against vincristine-resistant human KB cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23981529]
    KB IC50
    > 25 μg/mL
    Compound: vincristine
    Cytotoxicity against vincristine-sensitive human KB cells in presence of 0.1 ug/ml vincristine
    Cytotoxicity against vincristine-sensitive human KB cells in presence of 0.1 ug/ml vincristine
    		[PMID: 21428274]
    KB 3-1 IC50
    1230.48 nM
    Compound: VCR
    inhibitory concentration against human MDR KB/V cell line
    inhibitory concentration against human MDR KB/V cell line
    		[PMID: 15324905]
    KB-V1 IC50
    2035 nM
    Compound: Vincristine
    Antiproliferative activity against KBV1 cells expressing MDR1
    Antiproliferative activity against KBV1 cells expressing MDR1
    		[PMID: 17228873]
    KB-V1 IC50
    2035 nM
    Compound: Vincristine
    Antiproliferative activity against human KBV1 cells after 3 days by SRB assay
    Antiproliferative activity against human KBV1 cells after 3 days by SRB assay
    		[PMID: 19041247]
    KB-V1 IC50
    2035 nM
    Compound: vincristine
    Antiproliferative activity against KBV1cells
    Antiproliferative activity against KBV1cells
    		[PMID: 17416524]
    KB-V1 IC50
    8571 nM
    Compound: Vincristine
    Antiproliferative activity against human KB-V1 cells measured after 72 hrs by SRB assay
    Antiproliferative activity against human KB-V1 cells measured after 72 hrs by SRB assay
    		[PMID: 34794817]
    KB/VJ300 IC50
    0.8 μM
    Compound: Vincristine
    Antiproliferative activity against human KB/VJ300 cells assessed as reduction in cell growth after 72 hrs by MTT assay
    Antiproliferative activity against human KB/VJ300 cells assessed as reduction in cell growth after 72 hrs by MTT assay
    		[PMID: 31642315]
    KB/VJ300 IC50
    1.2 μM
    Compound: vincristine
    Cytotoxicity against human KB/VJ300 cells
    Cytotoxicity against human KB/VJ300 cells
    		[PMID: 17939738]
    KB/VJ300 IC50
    1.2 μM
    Compound: vincristine
    Cytotoxicity against vincristine resistant human KB/VJ300 cells
    Cytotoxicity against vincristine resistant human KB/VJ300 cells
    		[PMID: 18778099]
    KB/VJ300 IC50
    1.335 μM
    Compound: vincristine
    Cytotoxicity against human KB/VJ300 cells
    Cytotoxicity against human KB/VJ300 cells
    		[PMID: 17608533]
    KB/VJ300 IC50
    2.6 μM
    Compound: Vincristine
    Cytotoxicity against human KB/VJ300 cells after 72 hrs by MTT assay
    Cytotoxicity against human KB/VJ300 cells after 72 hrs by MTT assay
    		[PMID: 30869890]
    KB/VJ300 IC50
    3.9 μM
    Compound: Vincristine
    Growth inhibition of human KB/VJ300 cells after 72 hrs by MTT assay
    Growth inhibition of human KB/VJ300 cells after 72 hrs by MTT assay
    		[PMID: 29746134]
    KB/VJ300 IC50
    5.4 μg/mL
    Compound: vincristine
    Cytotoxicity against vincristine-resistant human KB/VJ300 cells
    Cytotoxicity against vincristine-resistant human KB/VJ300 cells
    		[PMID: 25333996]
    KB/VJ300 IC50
    5.9 μM
    Compound: Vincristine
    Cytotoxicity against human KB/VJ300 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human KB/VJ300 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27759387]
    KB/VJ300 IC50
    6.6 μM
    Compound: Vincristine
    Growth inhibition of human KB/VJ300 cells after 72 hrs by MTT assay
    Growth inhibition of human KB/VJ300 cells after 72 hrs by MTT assay
    		[PMID: 26918761]
    KB/VJ300 IC50
    7.5 μM
    Compound: Vincristine
    Cytotoxicity against human KB/VJ300 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human KB/VJ300 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26717050]
    KB/VJ300 IC50
    > 25 μg/mL
    Compound: vincristine
    Cytotoxicity in vincristine-resistant human KB/VJ300 cells in presence of 0.1 ug/ml vincristine
    Cytotoxicity in vincristine-resistant human KB/VJ300 cells in presence of 0.1 ug/ml vincristine
    		[PMID: 21428274]
    L02 IC50
    0.06 μM
    Compound: VCR
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    		[PMID: 30852384]
    L02 IC50
    0.2 μM
    Compound: VCR
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 29886320]
    L02 IC50
    0.3 μM
    Compound: VCR
    Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 33636536]
    L1210 IC50
    0.0034 μM
    Compound: Vincristine
    Concentration required to inhibit proliferation of cultured lymphoid leukemia L1210 cells to 50% growth over 48 hours
    Concentration required to inhibit proliferation of cultured lymphoid leukemia L1210 cells to 50% growth over 48 hours
    		[PMID: 1433180]
    L1210 IC50
    0.73 nM
    Compound: vincristine
    Inhibitory activity against growth of L1210 cell line
    Inhibitory activity against growth of L1210 cell line
    		[PMID: 9554885]
    L1210 IC50
    3.4 nM
    Compound: Vincristine
    The compound was tested in vitro for growth of inhibitory activity against lymphoid leukemia L1210 cells
    The compound was tested in vitro for growth of inhibitory activity against lymphoid leukemia L1210 cells
    		[PMID: 2795608]
    L1210 IC50
    3.4 nM
    Compound: vincristine
    Concentration that inhibits proliferation of cultured lymphoid leukemia L1210 cells to 50% control growth during 48 h
    Concentration that inhibits proliferation of cultured lymphoid leukemia L1210 cells to 50% control growth during 48 h
    		[PMID: 1479582]
    L1210 IC50
    4.85 nM
    Compound: 2
    Tested for the inhibition of L1210 cell proliferation.
    Tested for the inhibition of L1210 cell proliferation.
    		[PMID: 2066973]
    L1210 IC50
    6 nM
    Compound: 2
    Cytotoxicity against mouse L1210 cells
    Cytotoxicity against mouse L1210 cells
    		[PMID: 22247789]
    LLC-PK1 GI50
    0.03 μM
    Compound: vincristine
    Growth inhibition of pig LLC-PK1 cells
    Growth inhibition of pig LLC-PK1 cells
    		[PMID: 21344920]
    LNCaP IC50
    2.6 μM
    Compound: Vincristine
    Cytotoxicity activity against human LNCaP cells assessed as reduction in cell viability
    Cytotoxicity activity against human LNCaP cells assessed as reduction in cell viability
    		[PMID: 32531682]
    Leukemia cell GI50
    0.1 μM
    Compound: Vincristine
    Cell growth inhibition of human Leukemia cancer cells incubated for 48 hrs by SRB assay
    Cell growth inhibition of human Leukemia cancer cells incubated for 48 hrs by SRB assay
    		[PMID: 38640869]
    Leukemia cell GI50
    0.1 μM
    Compound: vincristine
    Cytotoxicity against human leukemia cells after 48 hrs
    Cytotoxicity against human leukemia cells after 48 hrs
    		[PMID: 23685944]
    MCF-T IC50
    435.85 nM
    Compound: Vincristine
    Cytotoxicity against human MCF-T cells assessed as cell survival measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF-T cells assessed as cell survival measured after 72 hrs by MTT assay
    		[PMID: 33360797]
    MCF7 ED50
    0.01 μg/mL
    Compound: vincristine
    Cytotoxicity against human MCF7 cells by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells by sulforhodamine B assay
    		[PMID: 18473435]
    MCF7 ED50
    12.1 nM
    Compound: Vincristine
    Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay
    		[PMID: 21296579]
    MCF7 GI50
    0.018 μM
    Compound: VCR
    Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay
    		[PMID: 21284385]
    MCF7 GI50
    1.5 nM
    Compound: 2
    Cytotoxicity against human MCF7 cells
    Cytotoxicity against human MCF7 cells
    		[PMID: 19147348]
    MCF7 IC50
    0.0006 μM
    Compound: vincristine
    Cytotoxic activity against drug-sensitive Pgp-, MRP1-deficient human MCF7 cells after 48 hrs by sulforhodamine B assay in presence of 50 nM vinblastin
    Cytotoxic activity against drug-sensitive Pgp-, MRP1-deficient human MCF7 cells after 48 hrs by sulforhodamine B assay in presence of 50 nM vinblastin
    		[PMID: 21680190]
    MCF7 IC50
    0.02 μM
    Compound: vincristine
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 16539377]
    MCF7 IC50
    0.02 μM
    Compound: vincristrine
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    MCF7 IC50
    0.029 μM
    Compound: VCR
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    MCF7 IC50
    0.05 μg/mL
    Compound: vincristine
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 16480866]
    MCF7 IC50
    0.098 μM
    Compound: VCT
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27149641]
    MCF7 IC50
    0.15 μg/mL
    Compound: vincristine
    Cytotoxicity against human MCF7 cells by clonogenic assay
    Cytotoxicity against human MCF7 cells by clonogenic assay
    		[PMID: 16480866]
    MCF7 IC50
    0.3 μM
    Compound: Vincristine
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 27187865]
    MCF7 IC50
    0.6 nM
    Compound: vincristine
    Growth inhibition of Pgp deficient MCF7 cells expressing MRP1
    Growth inhibition of Pgp deficient MCF7 cells expressing MRP1
    		[PMID: 17567121]
    MCF7 IC50
    0.84 nM
    Compound: vincristine
    Inhibitory activity against growth of MCF-7 cell line
    Inhibitory activity against growth of MCF-7 cell line
    		[PMID: 9554885]
    MCF7 IC50
    0.89 μM
    Compound: Vincristine
    Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33477020]
    MCF7 IC50
    0.9 μM
    Compound: Vincristine
    Antitumor activity against human MCF7 cells incubated for 48 hrs by CCK8 assay
    Antitumor activity against human MCF7 cells incubated for 48 hrs by CCK8 assay
    		[PMID: 37229830]
    MCF7 IC50
    0.92 μM
    Compound: Vincristine
    Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33477020]
    MCF7 IC50
    1.3 μM
    Compound: Vincristine
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    MCF7 IC50
    13 nM
    Compound: VCR
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23981529]
    MCF7 IC50
    2 nM
    Compound: Vincristine
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 22119129]
    MCF7 IC50
    2 nM
    Compound: vincristin
    Antiproliferative activity against human MCF7 cells after 5 days by microplate assay
    Antiproliferative activity against human MCF7 cells after 5 days by microplate assay
    		[PMID: 18513974]
    MCF7 IC50
    4.2 nM
    Compound: VC
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    MCF7 IC50
    4.3 μM
    Compound: VCT
    Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method
    Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method
    		[PMID: 25061803]
    MCF7-VP IC50
    0.0093 μM
    Compound: vincristine
    Cytotoxic activity against Pgp-deficient human MCF7/VP cells expressing MRP1 after 48 hrs by sulforhodamine B assay
    Cytotoxic activity against Pgp-deficient human MCF7/VP cells expressing MRP1 after 48 hrs by sulforhodamine B assay
    		[PMID: 21680190]
    MCF7-VP IC50
    9.3 nM
    Compound: vincristine
    Growth inhibition of Pgp deficient MCF7/VP cells expressing MRP1
    Growth inhibition of Pgp deficient MCF7/VP cells expressing MRP1
    		[PMID: 17567121]
    MDA-MB-231 IC50
    0.0045 μM
    Compound: Vincristine
    Antiproliferative activity against human MDA-MB-231 cells after 4 days by microplate assay
    Antiproliferative activity against human MDA-MB-231 cells after 4 days by microplate assay
    		[PMID: 17889547]
    MDA-MB-231 IC50
    0.02 μM
    Compound: Vincristine
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 26270803]
    MDA-MB-231 IC50
    1.6 nM
    Compound: VCR
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTitre-Blue assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTitre-Blue assay
    		[PMID: 24437936]
    MDA-MB-231 IC50
    15 nM
    Compound: Vincristine
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by alamar blue assay
    		[PMID: 19117761]
    MDA-MB-231 IC50
    4.5 nM
    Compound: Vincristine
    Antiproliferative activity against human MDA-MB-231 cells after 4 days
    Antiproliferative activity against human MDA-MB-231 cells after 4 days
    		[PMID: 17533132]
    MDA-MB-231 IC50
    6 nM
    Compound: Vincristine
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay
    		[PMID: 22119129]
    MDA-MB-231 IC50
    6 nM
    Compound: vincristin
    Antiproliferative activity against human MDA-MB-231 cells after 4 days by microplate assay
    Antiproliferative activity against human MDA-MB-231 cells after 4 days by microplate assay
    		[PMID: 18513974]
    MDA-MB-231 IC50
    9.86 μM
    Compound: Vincristine
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 30109000]
    MDA-MB-435 IC50
    0.02 μM
    Compound: Vincristine
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
    		[PMID: 26270803]
    MDA-MB-435 IC50
    0.29 nM
    Compound: Vincristine
    Antiproliferative activity against MDA435/LCC6 cells by ELISA
    Antiproliferative activity against MDA435/LCC6 cells by ELISA
    		[PMID: 17154505]
    MDA-MB-435 IC50
    0.63 nM
    Compound: Vincristine
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
    		[PMID: 17154505]
    MDA-MB-435 IC50
    26 nM
    Compound: Vincristine
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA
    Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA
    		[PMID: 17154505]
    MDA-MB-468 IC50
    0.4 nM
    Compound: VC
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    MDCK-II GI50
    0.34 μM
    Compound: vincristine
    Growth inhibition of dog MDCK2-MDR1 cells overexpressing human P-glycoprotein in presence of P-glycoprotein inhibitor LY335979
    Growth inhibition of dog MDCK2-MDR1 cells overexpressing human P-glycoprotein in presence of P-glycoprotein inhibitor LY335979
    		[PMID: 21344920]
    MDCK-II GI50
    0.43 μM
    Compound: vincristine
    Growth inhibition of dog MDCK2 cells in presence of P-glycoprotein inhibitor LY335979
    Growth inhibition of dog MDCK2 cells in presence of P-glycoprotein inhibitor LY335979
    		[PMID: 21344920]
    MDCK-II GI50
    106.59 μM
    Compound: vincristine
    Growth inhibition of dog MDCK2-MDR1 cells overexpressing human P-glycoprotein
    Growth inhibition of dog MDCK2-MDR1 cells overexpressing human P-glycoprotein
    		[PMID: 21344920]
    MDCK-II GI50
    2.65 μM
    Compound: vincristine
    Growth inhibition of dog MDCK2 cells
    Growth inhibition of dog MDCK2 cells
    		[PMID: 21344920]
    MES-SA IC50
    4.9 nM
    Compound: VC
    Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    MES-SA/Dx5 IC50
    uM μM
    Compound: vincristine
    In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation
    In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation
    		[PMID: 11728191]
    MHCC97H IC50
    21.2 nM
    Compound: Vincristine
    Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    MIA PaCa-2 IC50
    15 nM
    Compound: Vincristine
    Cytotoxicity against human MIAPaCa2 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human MIAPaCa2 cells after 48 hrs by alamar blue assay
    		[PMID: 19117761]
    MKN-28 IC50
    7.1 μM
    Compound: VCR
    Cytotoxicity against human MKN28 cells by MTT assay
    Cytotoxicity against human MKN28 cells by MTT assay
    		[PMID: 19679470]
    MOLT-4 IC50
    0.63 ng/mL
    Compound: Vincristine
    Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability
    Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability
    		[PMID: 29274817]
    MV4-11 IC50
    1.302 nM
    Compound: Vincristine
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    		[PMID: 37544183]
    MX1 IC50
    12 nM
    Compound: VCR
    Cytotoxicity against human MX1 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human MX1 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23981529]
    MX1 IC50
    75 nM
    Compound: VCR
    Cytotoxicity against taxol-resistant human MX1 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against taxol-resistant human MX1 cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23981529]
    Melanoma cell GI50
    0.2 μM
    Compound: vincristine
    Cytotoxicity against human melanoma cells after 48 hrs
    Cytotoxicity against human melanoma cells after 48 hrs
    		[PMID: 23685944]
    NCI-H157 IC50
    1.03 μM
    Compound: VCN
    Antiproliferative activity against human NCI-H157 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H157 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		10.1039/C5MD00529A
    NCI-H157 IC50
    1.03 μM
    Compound: Vincristine
    Cytotoxicity against human NCI-H157 cells by sulforhodamine B assay
    Cytotoxicity against human NCI-H157 cells by sulforhodamine B assay
    		[PMID: 25257911]
    NCI-H157 IC50
    1.03 μM
    Compound: Vincristine
    Cytotoxicity against human NCI-H157 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H157 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 31404864]
    NCI-H292 IC50
    0.04 μg/mL
    Compound: Vincristine
    Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
    		[PMID: 19027993]
    NCI-H295R IC50
    0.09 μM
    Compound: vincristine
    Cytotoxicity against human H295R cells by MTT assay
    Cytotoxicity against human H295R cells by MTT assay
    		[PMID: 16539377]
    NCI-H460 GI50
    0.003 μM
    Compound: Vincristine
    Compound was tested for growth inhibition of human non-small cell lung cancer NCI-H460 cell line
    Compound was tested for growth inhibition of human non-small cell lung cancer NCI-H460 cell line
    		[PMID: 15546733]
    NCI-H460 IC50
    0.00013 μM
    Compound: vincristine
    In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation
    In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation
    		[PMID: 11728191]
    NCI/ADR-RES IC50
    0.308 μM
    Compound: VCR
    Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay
    		[PMID: 27423028]
    NCI/ADR-RES IC50
    10.05 μM
    Compound: Vincristine
    Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay
    		[PMID: 33725657]
    NCI/ADR-RES IC50
    10.05 μM
    Compound: Vincristine
    Antitumor activity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay
    Antitumor activity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay
    		[PMID: 37229830]
    NCI/ADR-RES IC50
    2.93 mg/mL
    Compound: Vincristine
    Cytotoxicity against MCF-7/Adr cells.
    Cytotoxicity against MCF-7/Adr cells.
    		[PMID: 9207950]
    NCI/ADR-RES IC50
    62.8 μM
    Compound: Vincristine
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    NSCLC GI50
    0.2 μM
    Compound: vincristine
    Cytotoxicity against human NSCLC cells after 48 hrs
    Cytotoxicity against human NSCLC cells after 48 hrs
    		[PMID: 23685944]
    OE19 IC50
    0.05 μM
    Compound: vincristrine
    Cytotoxicity against human OE19 cells after 72 hrs by MTT assay
    Cytotoxicity against human OE19 cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    OE33 IC50
    0.03 μM
    Compound: vincristrine
    Cytotoxicity against human OE33 cells after 72 hrs by MTT assay
    Cytotoxicity against human OE33 cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    OVCAR-3 IC50
    0.02 μM
    Compound: vincristine
    Cytotoxicity against human Ovcar3 cells by MTT assay
    Cytotoxicity against human Ovcar3 cells by MTT assay
    		[PMID: 16539377]
    OVCAR-3 IC50
    0.02 μM
    Compound: vincristrine
    Cytotoxicity against human Ovcar3 cells after 72 hrs by MTT assay
    Cytotoxicity against human Ovcar3 cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    P388 EC50
    0.02 x 10-6 M
    Compound: Vincristine
    The compound was evaluated in vitro for the P388 cell spindle disruption.; 0.02-0.04
    The compound was evaluated in vitro for the P388 cell spindle disruption.; 0.02-0.04
    		10.1016/S0960-894X(00)80225-5
    P388 IC50
    1.2 nM
    Compound: Vincristine
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    		[PMID: 2778449]
    P388 IC50
    2 nM
    Compound: VCR
    In vitro inhibitory concentration required against murine P388 leukemic cells proliferation
    In vitro inhibitory concentration required against murine P388 leukemic cells proliferation
    		[PMID: 11140731]
    P388 IC50
    2.2 nM
    Compound: Vincristine
    Antiproliferative activity against P388 cells by ELISA
    Antiproliferative activity against P388 cells by ELISA
    		[PMID: 17154505]
    P388 IC50
    0.22 x 10-6 M
    Compound: Vincristine
    The compound was evaluated in vitro for the inhibition of P388D1 cell colony formation.
    The compound was evaluated in vitro for the inhibition of P388D1 cell colony formation.
    		10.1016/S0960-894X(00)80225-5
    P388 IC50
    0.0047 x 10-6 M
    Compound: Vincristine
    The compound was evaluated in vitro for the inhibition of murine leukemia P388D1 cell proliferation.
    The compound was evaluated in vitro for the inhibition of murine leukemia P388D1 cell proliferation.
    		10.1016/S0960-894X(00)80225-5
    P388/ADR IC50
    299 nM
    Compound: Vincristine
    Antiproliferative activity against adriamycin resistant P388 cells by ELISA
    Antiproliferative activity against adriamycin resistant P388 cells by ELISA
    		[PMID: 17154505]
    P388/ADR IC50
    4.5 nM
    Compound: Vincristine
    Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
    Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
    		[PMID: 17154505]
    PA-1 IC50
    0.01 μg/mL
    Compound: vincristine
    Cytotoxicity against human PA1 cells by MTT assay
    Cytotoxicity against human PA1 cells by MTT assay
    		[PMID: 16480866]
    PA-1 IC50
    1 μg/mL
    Compound: vincristine
    Cytotoxicity against human PA1 cells by clonogenic assay
    Cytotoxicity against human PA1 cells by clonogenic assay
    		[PMID: 16480866]
    PBL GI50
    1.2 μM
    Compound: Vincristine
    Cytotoxicity against human PBL assessed as reduction in cell viability in presence of mitogenic stimulus phytohaemagglutinin incubated for 72 hrs by MTT assay
    Cytotoxicity against human PBL assessed as reduction in cell viability in presence of mitogenic stimulus phytohaemagglutinin incubated for 72 hrs by MTT assay
    		[PMID: 32986419]
    PBL GI50
    7.5 μM
    Compound: Vincristine
    Cytotoxicity against human PBL assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human PBL assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32986419]
    PC-12 GI50
    104 nM
    Compound: vincristine
    Compound was evaluated for in vitro growth inhibition activity against multi drug resistant (MDR) PC-12 cell line.
    Compound was evaluated for in vitro growth inhibition activity against multi drug resistant (MDR) PC-12 cell line.
    		[PMID: 9873473]
    PC-3 ED50
    0.01 μg/mL
    Compound: vincristine
    Cytotoxicity against human PC3 cells by sulforhodamine B assay
    Cytotoxicity against human PC3 cells by sulforhodamine B assay
    		[PMID: 18473435]
    PC-3 ED50
    12.1 nM
    Compound: Vincristine
    Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay
    		[PMID: 21296579]
    PC-3 GI50
    0.018 μM
    Compound: VCR
    Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay
    Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay
    		[PMID: 21284385]
    PC-3 IC50
    0.07 μM
    Compound: Vincristine
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 26270803]
    PC-3 IC50
    5.31 μM
    Compound: Vincristine
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 30109000]
    PC-3 IC50
    > 25 μM
    Compound: Vincristine
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 29133061]
    PC-6 GI50
    1.14 nM
    Compound: vincristine
    Compound was evaluated for in vitro growth inhibition activity against sensitive PC-6 cell line.
    Compound was evaluated for in vitro growth inhibition activity against sensitive PC-6 cell line.
    		[PMID: 9873473]
    PLC-PRF-5 IC50
    12.7 nM
    Compound: Vincristine
    Antiproliferative activity against human PLC/PRF/5 cells
    Antiproliferative activity against human PLC/PRF/5 cells
    		[PMID: 22320354]
    PLC-PRF-5 IC50
    22.1 nM
    Compound: Vincristine
    Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    PT-45 IC50
    0.004 μM
    Compound: vincristine
    Cytotoxicity against human PT45 cells by MTT assay
    Cytotoxicity against human PT45 cells by MTT assay
    		[PMID: 16539377]
    PT-45 IC50
    0.004 μM
    Compound: vincristrine
    Cytotoxicity against human PT45 cells after 72 hrs by MTT assay
    Cytotoxicity against human PT45 cells after 72 hrs by MTT assay
    		[PMID: 17915851]
    Panel NCI-60 (60 carcinoma cell lines) GI50
    0.2 μM
    Compound: Vincristine
    Cell growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by SRB assay
    Cell growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by SRB assay
    		[PMID: 38640869]
    Renal cancer cell line GI50
    0.32 μM
    Compound: Vincristine
    Cell growth inhibition of human Renal cancer cells incubated for 48 hrs by SRB assay
    Cell growth inhibition of human Renal cancer cells incubated for 48 hrs by SRB assay
    		[PMID: 38640869]
    SMMC-7721 IC50
    0.003 μM
    Compound: VCR
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 29886320]
    SMMC-7721 IC50
    0.0103 μM
    Compound: VCR
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    		[PMID: 30852384]
    SMMC-7721 IC50
    0.27 μM
    Compound: VCR
    Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 33636536]
    SMMC-7721 IC50
    20.74 μg/mL
    Compound: Vincristine
    Cytotoxicity against human SMMC7721 cells by MTT assay
    Cytotoxicity against human SMMC7721 cells by MTT assay
    		[PMID: 14695795]
    SMMC-7721 IC50
    52.21 μM
    Compound: VCR
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    		[PMID: 19111465]
    SMMC-7721 IC50
    6.5 nM
    Compound: Vincristine
    Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    SMMC-7721 IC50
    < 0.12 μM
    Compound: vincristine
    Cytotoxicity against SMMC7721 cells after 48 hrs by MTT assay
    Cytotoxicity against SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 17604394]
    SNU-182 IC50
    35.9 nM
    Compound: Vincristine
    Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    SNU-387 IC50
    40.9 nM
    Compound: Vincristine
    Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    SNU-398 EC50
    0.012 μM
    Compound: vincristine
    Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay
    Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay
    		[PMID: 18197614]
    SNU-398 IC50
    46.7 nM
    Compound: Vincristine
    Antiproliferative activity against human SNU398 cells
    Antiproliferative activity against human SNU398 cells
    		[PMID: 22320354]
    SNU-398 IC50
    < 0.13 nM
    Compound: Vincristine
    Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    SNU-423 IC50
    10 nM
    Compound: Vincristine
    Cytotoxicity against human SNU423 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human SNU423 cells after 48 hrs by alamar blue assay
    		[PMID: 19117761]
    SNU-423 IC50
    18.4 nM
    Compound: Vincristine
    Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    SNU-449 IC50
    > 100 nM
    Compound: Vincristine
    Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    SNU-475 IC50
    29.3 nM
    Compound: Vincristine
    Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay
    		[PMID: 22320354]
    SiHa IC50
    0.01 μM
    Compound: Vincristine
    Cytotoxicity against human SiHa cells by MTT assay
    Cytotoxicity against human SiHa cells by MTT assay
    		[PMID: 28105271]
    T47D EC50
    0.043 μM
    Compound: vincristine
    Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay
    Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay
    		[PMID: 18197614]
    TERT-RPE1 IC50
    7.6 nM
    Compound: VC
    Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
    		[PMID: 38959729]
    Vero CC50
    1.1 μg/mL
    Compound: Vincristine
    Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay
    Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay
    		[PMID: 19217699]
    Vero IC50
    0.9 μM
    Compound: Vincristine
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay
    		[PMID: 27187865]
    Vero IC50
    1.1 μg/mL
    Compound: Vincristine
    Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay
    Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay
    		[PMID: 20619938]
    WRL68 IC50
    1.42 μg/mL
    Compound: vincristine
    Cytotoxicity against human WRL68 cells by MTT assay
    Cytotoxicity against human WRL68 cells by MTT assay
    		[PMID: 16480866]
    WRL68 IC50
    8.5 μg/mL
    Compound: vincristine
    Cytotoxicity against human WRL68 cells by clonogenic assay
    Cytotoxicity against human WRL68 cells by clonogenic assay
    		[PMID: 16480866]
    ZR-75-1 IC50
    0.04 μM
    Compound: vincristrine
    Cytotoxicity against human ZR751cells by SRB microtiter plate assay
    Cytotoxicity against human ZR751cells by SRB microtiter plate assay
    		[PMID: 17585747]
    In Vitro

    Vincristine (100 nM; 0-48 h) induces apoptosis in G1-phase enriched ALL-2 and ALL-5 cells without mitotic arrest (no MPM2 staining); it also induces apoptosis in G2-M phase enriched ALL-2 and ALL-5 cells in the presence of mitotic arrest (enhanced MPM2 staining)[2].
    Acute treatment with Vincristine (1 μM; 2 h) inhibits the proliferation of B16 melanoma cells, and its potency is lower than that of vinblastine (HY-13780) and vindesine (HY-16514)[4].
    Vincristine (5-2000 nM; 24-48 h) induces mRNA expression of ABCC2, ABCC3, PXR and CYP3A4 (10 nM, 48 h) in LS174T and A549 cells, and regulates the expression of ABCB1 and ABCC2 in Caco2 cells in a concentration- and time-dependent manner[5].
    Treatment of SGC7901 cells with Vincristine (0.5-1.5 μg/mL) upregulates the mRNA expression of Snail, Twist, MRP and Pgp, indicating that the epithelial-mesenchymal transition and multidrug resistance pathways are activated[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Vincristine Related Antibodies

    Cell Viability Assay[5]

    Cell Line: LS174T (human intestine carcinoma), Caco2 (human intestine adrenal carcinoma), A549 (human lung carcinoma)
    Concentration: 5, 10, 50, 100, 200, 500, 1000 nM
    Incubation Time: 48 h
    Result: Reduced viability in a concentration-dependent manner in LS174T and Caco2 cells; showed no decrease in viability in A549 cells even with elevated doses.
    In Vivo

    Vincristine (5-10 mg/kg; i.v.) induces significant tumor necrosis and reduces tumor blood flow in mice subcutaneously implanted with colon 38 adenocarcinoma[3].
    Vincristine (10 mg/kg; i.p.) induces significant tumor necrosis in subcutaneous multidrug-resistant P388 leukemia subline xenografts in mice[3].
    Vincristine (75 μg/kg; i.p.; daily; 10 days) induces peripheral neuropathic pain in mice, which is characterized by behavioral, electrophysiological, histopathological, oxidative stress and inflammatory changes[7].
    Vincristine (0.1 mg/kg; i.p.; daily; 7 days) induces dose- and duration-dependent peripheral neuropathic pain and oxidative stress in mice[8].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Neuropathic pain model in mouse (weight 20-22 g)[7]
    Dosage: 75 μg/kg
    Administration: i.p.; daily; 10 consecutive days
    Result: Induced significant mechanical and cold allodynia from day 11 to 21 (measured via von Frey and cold-plate tests); caused heat hyperalgesia and mechanical hyperalgesia (measured via hot-plate and paw pressure tests); decreased sensory nerve conduction velocity (SNCV) and sensory nerve action potential (SNAP) amplitudes; caused abnormal histopathological changes in sciatic nerve (loss of myelinated nerve fibers, irregularly arranged axons, swelling, increased vacuoles); increased levels of malondialdehyde (MDA), total calcium (TCA), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) in spinal cord tissue; decreased levels of total antioxidant capacity (T-AOC), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and interleukin-10 (IL-10) in spinal cord tissue.
    Animal Model: Chemotherapy-induced peripheral neuropathy in Swiss albino mouse (male, 22-25 g)[8]
    Dosage: 0.1 mg/kg
    Administration: i.p.; daily; 7 consecutive days
    Result: Induced significant thermal hyperalgesia on days 7, 10, and 14; induced significant thermal allodynia on days 7, 10, and 14; induced significant mechanical hyperalgesia; induced significant sciatic functional loss; induced significant increase in paw licking and elevation time in the acute and delayed phases of the formalin test; induced significant increase in total calcium levels in sciatic nerve homogenate; induced significant depletion of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and reduced glutathione (GSH) levels; induced significant elevation of lipid peroxidation (LPO) and nitric oxide (NO) levels in sciatic nerve tissue.
    Clinical Trial
    Molecular Weight

    824.96

    Formula

    C46H56N4O10
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (60.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.2122 mL 6.0609 mL 12.1218 mL
    5 mM 0.2424 mL 1.2122 mL 2.4244 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 98.60%

    SDS (393 KB)

    COA (262 KB) HNMR (443 KB) LCMS (95 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.2122 mL 6.0609 mL 12.1218 mL 30.3045 mL
    5 mM 0.2424 mL 1.2122 mL 2.4244 mL 6.0609 mL
    10 mM 0.1212 mL 0.6061 mL 1.2122 mL 3.0304 mL
    15 mM 0.0808 mL 0.4041 mL 0.8081 mL 2.0203 mL
    20 mM 0.0606 mL 0.3030 mL 0.6061 mL 1.5152 mL
    25 mM 0.0485 mL 0.2424 mL 0.4849 mL 1.2122 mL
    30 mM 0.0404 mL 0.2020 mL 0.4041 mL 1.0101 mL
    40 mM 0.0303 mL 0.1515 mL 0.3030 mL 0.7576 mL
    50 mM 0.0242 mL 0.1212 mL 0.2424 mL 0.6061 mL
    60 mM 0.0202 mL 0.1010 mL 0.2020 mL 0.5051 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Vincristine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Vincristine57-22-7Leurocristine NSC-67574 22-OxovincaleukoblastineNSC67574NSC 67574NSC-67574ApoptosisMicrotubule/TubulinMitosisCARABCB1ABCC3acute lymphoblastic leukemiabovine tubulinPXRABCC1gastric cancer stem-like cellsABCC2β-tubulinInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Vincristine
    Cat. No.:
    HY-N0488A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.